文献速递肿瘤 PET/CT神经核医学

PET/CT与脑MRI在临床T1期肺癌患者转移灶检测中的影响:来自大规模队列研究的发现

The impact of PET/CT and brain MRI for metastasis detection among patients with clinical T1-category lung cancer: Findings from a large-scale cohort study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-05-09

该大规模队列研究纳入2298例临床T1期肺癌患者,按结节大小和形态特征分层分析转移检出率。实性结节<8.0 mm和亚实性结节<10.0 mm患者未见转移;PET/CT代谢参数区分转移的截断值分别为SUVmax 1.09、SUVmean 0.26、SULpeak 0.31、MTV 0.55、TLG 0.81。接受PET/CT联合MRI者中,实性结节≥8.0 mm和亚实性结节≥10.0 mm患者总生存期更长(HR 0.44,p<0.001)。

要点

  • 实性结节<8.0 mm和亚实性结节<10.0 mm患者未观察到转移。
  • PET/CT代谢参数区分转移的截断值:SUVmax 1.09、SUVmean 0.26、SULpeak 0.31、MTV 0.55、TLG 0.81。
  • 实性结节≥8.0 mm和亚实性结节≥10.0 mm患者接受PET/CT联合MRI者总生存期更长(HR 0.44,p<0.001)。

核心结论

  • 对于实性结节<8.0 mm和亚实性结节<10.0 mm的患者,应谨慎评估PET/CT和MRI的必要性。
  • 对于实性结节≥8.0 mm和亚实性结节≥10.0 mm的患者,这些检查仍然必要且有益。

研究设计与样本

  • 大规模队列研究,纳入2298例临床T1期肺癌患者。
  • 按肿瘤大小和形态特征(实性和亚实性)分层测量转移检出率。
  • 基于PET/CT代谢参数(SUVmax/SUVmean/SULpeak/MTV/TLG)进行ROC分析确定区分转移的截断值。
  • 对术后患者进行Kaplan-Meier生存分析,比较接受与未接受PET/CT联合MRI者的总生存期。

主要发现

  • 实性结节<8.0 mm和亚实性结节<10.0 mm患者中未观察到转移。
  • PET/CT代谢参数区分转移的截断值分别为:SUVmax 1.09、SUVmean 0.26、SULpeak 0.31、MTV 0.55、TLG 0.81。
  • 实性结节≥8.0 mm和亚实性结节≥10.0 mm患者中,接受PET/CT联合MRI者较未接受者总生存期更长(HR 0.44,p<0.001)。
  • 实性结节≥8.0 mm患者中,接受PET/CT联合MRI者较未接受者总生存期更长(HR 0.12,p<0.001)。
  • 亚实性结节≥10.0 mm患者中,接受PET/CT联合MRI者较未接受者总生存期差异未达统计学显著(HR 0.61,p=0.075)。

关键数值与推荐

  • 实性结节<8.0 mm和亚实性结节<10.0 mm患者中未观察到转移。
  • PET/CT代谢参数区分转移的截断值:SUVmax 1.09、SUVmean 0.26、SULpeak 0.31、MTV 0.55、TLG 0.81。
  • 实性结节≥8.0 mm和亚实性结节≥10.0 mm患者接受PET/CT联合MRI者总生存期更长(HR 0.44,p<0.001)。
  • 实性结节≥8.0 mm患者接受PET/CT联合MRI者总生存期更长(HR 0.12,p<0.001)。
  • 亚实性结节≥10.0 mm患者接受PET/CT联合MRI者总生存期差异未达统计学显著(HR 0.61,p=0.075)。

临床怎么用

  • 作者认为,对于实性结节<8.0 mm和亚实性结节<10.0 mm的患者,应谨慎评估PET/CT和MRI的必要性。
  • 作者认为,对于实性结节≥8.0 mm和亚实性结节≥10.0 mm的患者,PET/CT和MRI仍然必要且有益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: [18F]-FDG PET/CT and brain MRI are common approaches to detect metastasis in patients of lung cancer. Current guidelines for the use of PET/CT and MRI in clinical T1-category lung cancer lack risk-based stratification and require optimization. This study stratified patients based on metastatic risk in terms of the lesions' size and morphological characteristics. METHODS: The detection rate of metastasis was measured in different sizes and morphological characteristics (solid and sub-solid) of tumors. To confirm the cut-off value for discriminating metastasis and overall survival (OS) prediction, the receiver operating characteristic (ROC) analysis was performed based on PET/CT metabolic parameters (SUVmax/SUVmean/SULpeak/MTV/TLG), followed by Kaplan-Meier analysis for survival in post-operation patients with and without PET/CT plus MRI. RESULTS: 2,298 patients were included. No metastasis was observed in patients with solid nodules < 8.0 mm and sub-solid nodules < 10.0 mm. The cut-off of PET/CT metabolic parameters on discriminating metastasis were 1.09 (SUVmax), 0.26 (SUVmean), 0.31 (SULpeak), 0.55 (MTV), and 0.81 (TLG), respectively. Patients undergoing PET/CT plus MRI exhibited longer OS compared to those who did not receive it in solid nodules ≥ 8.0 mm & sub-solid nodules ≥ 10.0 mm (HR, 0.44; p < 0.001); in solid nodules ≥ 8.0 mm (HR, 0.12; p<0.001) and in sub-solid nodules ≥ 10.0 mm (HR; 0.61; p=0.075), respectively. Compared to patients with metabolic parameters lower than cut-off values, patients with higher metabolic parameters displayed shorter OS: SUVmax (HR, 12.94; p < 0.001), SUVmean (HR, 11.33; p <0.001), SULpeak (HR, 9.65; p < 0.001), MTV (HR, 9.16; p = 0.031), and TLG (HR, 12.06; p < 0.001). CONCLUSION: The necessity of PET/CT and MRI should be cautiously evaluated in patients with solid nodules < 8.0 mm and sub-solid nodules < 10.0 mm, however, these examinations remained essential and beneficial for patients with solid nodules ≥ 8.0 mm and sub-solid nodules ≥ 10.0 mm.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Feng Y, Cheng B, Zhan S, et al. The impact of PET/CT and brain MRI for metastasis detection among patients with clinical T1-category lung cancer: Findings from a large-scale cohort study. Eur J Nucl Med Mol Imaging. 2024. PMID: 38722381. doi:10.1007/s00259-024-06740-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。